Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.


5 Dec 150x110ASH 2016 Data Review Meeting

Genmab hosted an ASH 2016 Data Review Meeting on December 5 in San Diego, CA.The meeting included the presentation of daratumumab data presented at the 2016 American Society of Hematology Annual Meeting (December 3-6).The event was also be webcast and an archive of the webcast is available here.  To download the slides of the presentation, click hereThis meeting was NOT an official program of the ASH Annual Meeting. 

nov 102016 Capital Markets Day

Genmab hosted a Capital Markets Day on November 10, 2016 featuring a variety of Genmab speakers who provided updates on our business including the clinical and pre-clinical pipelines, proprietary next generation antibody technologies and R&D capabilities. Click here to listen to the webcast replay.  Click here to download the presentation.

Third Quarter 2016 Financial Results

Genmab published its Third Quarter 2016 financial report and held an investor conference call on November 2. Click the following links to access the archived call: Click here to listen to the webcast. Click here to view the report. Click here to view the presentation. Click here to download the podcast.